Do analysts prefer BTCY or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BTCY or OSRH?

Biotricity has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biotricity $12.06M 0.30 -$14.09M -$0.16 N/A OSR $2.91M 3.74 -$27.06M -$0.33 N/A

Is BTCY or OSRH more profitable?

Biotricity has a net margin of -80.42% compared to OSR's net margin of -363.26%. Biotricity's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% OSR -363.26% -7.24% -5.41%

Do analysts prefer FEMY or BTCY?

Femasys presently has a consensus price target of $106.67, indicating a potential upside of 2,352.11%. Given Femasys' stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, FEMY or BTCY?

Biotricity has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 5.74 -$18.63M -$5.40 N/A Biotricity $12.06M 0.30 -$14.09M -$0.16 N/A

Is FEMY or BTCY more profitable?

Biotricity has a net margin of -80.42% compared to Femasys' net margin of -521.97%. Biotricity's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Biotricity -80.42% N/A -188.47%

Do analysts prefer BTCY or CODX?

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 2,091.56%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BTCY or CODX more profitable?

Biotricity has a net margin of -80.42% compared to Co-Diagnostics' net margin of -6,760.63%. Biotricity's return on equity of 0.00% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Co-Diagnostics -6,760.63% -164.92% -141.15%

Do analysts rate BTCY or ICU?

SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 64.61%. Given SeaStar Medical's stronger consensus rating and higher possible upside, analysts plainly believe SeaStar Medical is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SURG or BTCY?

SurgePays currently has a consensus target price of $3.50, suggesting a potential upside of 743.58%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts clearly believe SurgePays is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SURG or BTCY more profitable?

SurgePays has a net margin of -64.91% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Biotricity -80.42% N/A -188.47%

Biotricity (BTCY) Competitors

$0.13 +0.00 (+3.23%)

As of 03:59 PM Eastern

Compare

BTCY vs. OSRH, FEMY, CODX, ICU, and SURG

Should you buy Biotricity stock or one of its competitors? MarketBeat compares Biotricity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biotricity include OSR (OSRH), Femasys (FEMY), Co-Diagnostics (CODX), SeaStar Medical (ICU), and SurgePays (SURG). These companies are all part of the "medical equipment" industry.

How does Biotricity compare to OSR?

Biotricity (NASDAQ:BTCY) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Biotricity has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.30	-$14.09M	-$0.16	N/A
OSR	$2.91M	3.74	-$27.06M	-$0.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biotricity has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, OSR has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, OSR had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for OSR and 0 mentions for Biotricity. OSR's average media sentiment score of 0.62 beat Biotricity's score of 0.00 indicating that OSR is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
OSR	Positive

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 1.6% of Biotricity shares are owned by insiders. Comparatively, 36.8% of OSR shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biotricity has a net margin of -80.42% compared to OSR's net margin of -363.26%. Biotricity's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
OSR	-363.26%	-7.24%	-5.41%

Summary

Biotricity and OSR tied by winning 7 of the 14 factors compared between the two stocks.

How does Biotricity compare to Femasys?

Femasys (NASDAQ:FEMY) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Femasys presently has a consensus price target of $106.67, indicating a potential upside of 2,352.11%. Given Femasys' stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Femasys has a beta of -2.23, indicating that its share price is 323% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Biotricity has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	5.74	-$18.63M	-$5.40	N/A
Biotricity	$12.06M	0.30	-$14.09M	-$0.16	N/A

65.3% of Femasys shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 1.6% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Femasys had 3 more articles in the media than Biotricity. MarketBeat recorded 3 mentions for Femasys and 0 mentions for Biotricity. Femasys' average media sentiment score of 0.64 beat Biotricity's score of 0.00 indicating that Femasys is being referred to more favorably in the media.

Company	Overall Sentiment
Femasys	Positive
Biotricity	Neutral

Biotricity has a net margin of -80.42% compared to Femasys' net margin of -521.97%. Biotricity's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Biotricity	-80.42%	N/A	-188.47%

Summary

Femasys beats Biotricity on 9 of the 16 factors compared between the two stocks.

How does Biotricity compare to Co-Diagnostics?

Biotricity (NASDAQ:BTCY) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Co-Diagnostics had 8 more articles in the media than Biotricity. MarketBeat recorded 8 mentions for Co-Diagnostics and 0 mentions for Biotricity. Co-Diagnostics' average media sentiment score of 0.72 beat Biotricity's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
Co-Diagnostics	Positive

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 2,091.56%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biotricity has a net margin of -80.42% compared to Co-Diagnostics' net margin of -6,760.63%. Biotricity's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

3.9% of Biotricity shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 1.6% of Biotricity shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biotricity has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

Biotricity has higher revenue and earnings than Co-Diagnostics. Biotricity is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.30	-$14.09M	-$0.16	N/A
Co-Diagnostics	$620K	18.33	-$46.90M	-$15.77	N/A

Summary

Co-Diagnostics beats Biotricity on 10 of the 16 factors compared between the two stocks.

How does Biotricity compare to SeaStar Medical?

Biotricity (NASDAQ:BTCY) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 64.61%. Given SeaStar Medical's stronger consensus rating and higher possible upside, analysts plainly believe SeaStar Medical is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, SeaStar Medical had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for SeaStar Medical and 0 mentions for Biotricity. SeaStar Medical's average media sentiment score of 1.89 beat Biotricity's score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
SeaStar Medical	Very Positive

Biotricity has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, suggesting that its share price is 205% less volatile than the broader market.

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 1.6% of Biotricity shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Biotricity has a net margin of -80.42% compared to SeaStar Medical's net margin of -828.62%. Biotricity's return on equity of 0.00% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
SeaStar Medical	-828.62%	-146.29%	-96.48%

SeaStar Medical has lower revenue, but higher earnings than Biotricity. SeaStar Medical is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.30	-$14.09M	-$0.16	N/A
SeaStar Medical	$1.23M	15.80	-$12.15M	-$4.80	N/A

Summary

Biotricity and SeaStar Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Biotricity compare to SurgePays?

SurgePays (NASDAQ:SURG) and Biotricity (NASDAQ:BTCY) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

SurgePays has a net margin of -64.91% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Biotricity	-80.42%	N/A	-188.47%

SurgePays currently has a consensus target price of $3.50, suggesting a potential upside of 743.58%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts clearly believe SurgePays is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 1.6% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SurgePays had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for Biotricity. SurgePays' average media sentiment score of 1.87 beat Biotricity's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Overall Sentiment
SurgePays	Very Positive
Biotricity	Neutral

SurgePays has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Biotricity has lower revenue, but higher earnings than SurgePays. Biotricity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.18	-$36.07M	-$1.94	N/A
Biotricity	$12.06M	0.30	-$14.09M	-$0.16	N/A

Summary

SurgePays beats Biotricity on 9 of the 16 factors compared between the two stocks.

Get Biotricity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTCY vs. The Competition

Export

Metric	Biotricity	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.66M	$44.77M	$6.79B	$12.54B
Dividend Yield	N/A	1.08%	2.66%	6.15%
P/E Ratio	-0.12	20.32	27.46	25.27
Price / Sales	0.30	31.60	582.89	119.24
Price / Cash	N/A	18.87	48.53	58.59
Price / Book	-0.10	8.31	10.95	6.61
Net Income	-$14.09M	-$16.77M	$3.57B	$336.83M
7 Day Performance	-0.78%	8.44%	2.58%	2.54%
1 Month Performance	12.08%	1.14%	1.67%	0.46%
1 Year Performance	-67.86%	-2.36%	35.92%	29.41%

Biotricity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTCY Biotricity	N/A	$0.13 +3.2%	N/A	-66.5%	$3.66M	$12.06M	N/A	40	Upcoming Earnings Gap Up
OSRH OSR	0.6503 of 5 stars	$0.39 +2.0%	N/A	-77.1%	$13.49M	$2.91M	N/A	N/A
FEMY Femasys	2.5717 of 5 stars	$4.04 -3.6%	$106.67 +2,540.3%	-78.4%	$12.65M	$2.29M	N/A	30
CODX Co-Diagnostics	3.1081 of 5 stars	$3.37 +1.2%	$67.50 +1,903.0%	-63.1%	$12.27M	$620K	N/A	100	News Coverage Short Interest Decrease Gap Up Trading Halted
ICU SeaStar Medical	3.2436 of 5 stars	$3.12 +2.0%	$8.00 +156.4%	-13.8%	$12.23M	$1.23M	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTCY) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biotricity (BTCY) Competitors

BTCY vs. OSRH, FEMY, CODX, ICU, and SURG

How does Biotricity compare to OSR?

Summary

How does Biotricity compare to Femasys?

Summary

How does Biotricity compare to Co-Diagnostics?

Summary

How does Biotricity compare to SeaStar Medical?

Summary

How does Biotricity compare to SurgePays?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biotricity (BTCY) Competitors

BTCY vs. OSRH, FEMY, CODX, ICU, and SURG

How does Biotricity compare to OSR?

Which has preferable valuation and earnings, BTCY or OSRH?

Do analysts prefer BTCY or OSRH?

Which has more volatility & risk, BTCY or OSRH?

Does the media refer more to BTCY or OSRH?

Do insiders & institutionals have more ownership in BTCY or OSRH?

Is BTCY or OSRH more profitable?

Summary

How does Biotricity compare to Femasys?

Do analysts prefer FEMY or BTCY?

Which has more risk and volatility, FEMY or BTCY?

Which has higher valuation and earnings, FEMY or BTCY?

Do insiders and institutionals believe in FEMY or BTCY?

Does the media prefer FEMY or BTCY?

Is FEMY or BTCY more profitable?

Summary

How does Biotricity compare to Co-Diagnostics?

Does the media refer more to BTCY or CODX?

Do analysts prefer BTCY or CODX?

Is BTCY or CODX more profitable?

Do insiders & institutionals believe in BTCY or CODX?

Which has more risk & volatility, BTCY or CODX?

Which has better earnings & valuation, BTCY or CODX?

Summary

How does Biotricity compare to SeaStar Medical?

Do analysts rate BTCY or ICU?

Does the media refer more to BTCY or ICU?

Which has more volatility & risk, BTCY or ICU?

Do insiders and institutionals hold more shares of BTCY or ICU?

Is BTCY or ICU more profitable?

Which has higher earnings and valuation, BTCY or ICU?

Summary

How does Biotricity compare to SurgePays?

Is SURG or BTCY more profitable?

Do analysts recommend SURG or BTCY?

Do institutionals & insiders hold more shares of SURG or BTCY?

Does the media refer more to SURG or BTCY?

Which has more risk and volatility, SURG or BTCY?

Which has stronger valuation and earnings, SURG or BTCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools